NDATOPICALCREAM
Approved
Jul 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOTRISONE (betamethasone dipropionate; clotrimazole) by Merck & Co. is [see ] . First approved in 1984.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lotrisone is a fixed-dose topical cream combining betamethasone dipropionate (a potent corticosteroid) and clotrimazole (an antifungal) for treating fungal skin infections including tinea pedis, tinea cruris, and tinea corporis. The corticosteroid reduces inflammation and immune response while the antifungal targets fungal pathogens; the precise mechanism for tinea treatment remains incompletely characterized. This combination therapy addresses both the fungal infection and associated inflammatory symptoms in a single formulation.
LOE Approaching
As an established topical product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team likely focuses on lifecycle extension and generic transition planning rather than growth.
Mechanism of Action
[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Lotrisone offers limited career growth as the product approaches loss of exclusivity; roles focus on defending market share against generics and optimizing profitability rather than expansion. Career mobility may be constrained by the product's mature lifecycle, making this assignment better suited as a stabilizing role or transition point rather than a high-visibility growth opportunity.
Brand Manager
Worked on LOTRISONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.